News & Views - Page 42 of 53 - Telix Pharmaceuticals Limited

Launch of the International NOBLE Registry of Telix’s SPECT-Based Prostate Cancer Imaging Agent

Telix announces the launch of the international NOBLE Registry of Telix’s ‘rest of world’ prostate cancer imaging agent and the dosing of the first patient

Australian TGA Accepts Telix’s Prostate Cancer Imaging Product Submission and Commences Priority Evaluation Process

Telix announces the Australian Therapeutic Goods Administration has accepted its prostate cancer imaging product submission and commenced the priority evaluation process

Telix Pharmaceuticals Limited – Notice of Annual General Meeting 2021

Telix Pharmaceuticals provides notice of The Annual General Meeting of Shareholders on Wednesday 12 May 2021

Telix Pharmaceuticals and Grand River Aseptic Manufacturing Complete Agreement for Commercial Manufacturing of Illuccix®

Telix announces it has completed an agreement with Grand River Aseptic Manufacturing to perform GMP manufacturing of Telix’s prostate cancer imaging product.

Telix Appoints Darren Patti, Chief Operating Officer, Telix Pharmaceuticals (US) Inc.

Telix is delighted to announce the appointment of Darren Patti as Chief Operating Officer, Telix Pharmaceuticals US (Inc). Darren brings with him over 15 years’ experience in radiopharmacy network management and operations, including new radiopharmaceuticals implementation and compliance.

Telix Pharmaceuticals and ITM Complete Global Agreements for Lutetium-177 Radioisotope Supply

Telix announces it has extended its non-exclusive global clinical and commercial supply agreements with Garching-based ITM AG

Telix Appoints Sébastien Linard as General Manager, Telix European Manufacturing Facility

Telix is delighted to announce the appointment of Sébastien Linard to the position of General Manager of Telix’s European Manufacturing in Seneffe, Belgium.

AUDIO LINK NOT INCLUDED – Telix Pharmaceuticals Releases Results for the Year Ended 31 December 2020 and 2020 Annual Report

Telix Pharmaceuticals Limited Releases Full-Year 2020 Results and 2020 Annual Report.

Telix and Kanazawa University Cleared to Commence Prostate Cancer Imaging Study in Japan

Telix Japan receives Clinical Trial Notification (CTN) clearance to commence a Phase I trial of its prostate cancer imaging product in Japan.

Telix FY2020 Results and Company Update Conference Call

Telix to present the Company’s FY2020 results together with an update on Telix’s operations.